CanBas Co., Ltd. (JP:4575)
:4575
Want to see JP:4575 full AI Analyst Report?
Top Page
CanBas Co., Ltd.
(4575)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥719.00
▼(-8.64% Downside)
Action:ReiteratedDate:02/04/26
The score is primarily held back by weak financial performance—persistent losses, minimal revenue, and ongoing cash burn—despite balance-sheet de-risking from zero debt and higher equity. Technical indicators are moderately supportive with price above key medium-term averages and positive momentum, while valuation remains constrained by a negative P/E and no dividend yield.
Positive Factors
Deleveraged balance sheet (zero debt, higher equity)
Zero reported debt and a material equity increase materially reduce refinancing and leverage risk, giving management greater strategic flexibility. Over a multimonth horizon this improves the firm's ability to fund R&D, negotiate partnerships, and survive development timelines without immediate debt pressures.
Negative Factors
Persistent operating and net losses; revenue near zero
Recurring operating and net losses with effectively zero revenue reflect a pre-commercial biotech profile and imply the company cannot self-fund development. Over a multi-month horizon this increases execution risk, reliance on external capital, and uncertainty around when commercial revenues will emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraged balance sheet (zero debt, higher equity)
Zero reported debt and a material equity increase materially reduce refinancing and leverage risk, giving management greater strategic flexibility. Over a multimonth horizon this improves the firm's ability to fund R&D, negotiate partnerships, and survive development timelines without immediate debt pressures.
Read all positive factors
CanBas Co., Ltd. (4575) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥14.33B
Dividend YieldN/A
Average Volume (3M)268.48K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue GrowthN/A
EPS Growth14.03%
CountryJP
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,713,655
10 Day Avg. Volume208,910
30 Day Avg. Volume268,476
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-29.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CanBas Co., Ltd. Business Overview & Revenue Model
Company Description
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I ...
How the Company Makes Money
CanBas Co., Ltd. primarily generates revenue through pharmaceutical R&D-related monetization, including (1) licensing and out-licensing arrangements in which it grants partners rights to develop and/or commercialize its drug candidates or related ...
CanBas Co., Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 108.94M |
| Gross Profit | -820.00M | -984.00M | -671.00M | -608.00M | -322.00M |
| EBITDA | -1.16B | 53.65M | -1.28B | -848.65M | -522.28M |
| Net Income | -1.16B | -1.21B | -1.24B | -855.58M | -531.03M |
Balance Sheet | |||||
| Total Assets | 3.05B | 2.43B | 2.09B | 790.71M | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 1.89B | 1.62B | 737.77M | 1.15B |
| Total Debt | 0.00 | 0.00 | 0.00 | 367.34M | 749.99M |
| Total Liabilities | 107.00M | 91.99M | 153.85M | 540.02M | 857.64M |
| Stockholders Equity | 2.94B | 2.34B | 1.93B | 250.69M | 437.97M |
Cash Flow | |||||
| Free Cash Flow | -771.45M | -1.28B | -1.40B | -719.81M | -688.57M |
| Operating Cash Flow | -771.45M | -1.28B | -1.40B | -719.81M | -688.57M |
| Investing Cash Flow | 122.00K | 0.00 | 0.00 | 182.00K | 0.00 |
| Financing Cash Flow | 1.75B | 1.54B | 2.27B | 282.75M | 728.80M |
CanBas Co., Ltd. Technical Analysis
Negative
787.00
Price Trends
796.42
Negative
814.16
Negative
934.98
Negative
Market Momentum
-10.99
Negative
46.05
Neutral
36.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Negative. The current price of 787 is above the 20-day moving average (MA) of 743.35, below the 50-day MA of 796.42, and below the 200-day MA of 934.98, indicating a neutral trend. The MACD of -10.99 indicates Negative momentum. The RSI at 46.05 is Neutral, neither overbought nor oversold. The STOCH value of 36.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4575.
CanBas Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.84B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥14.33B | -17.96 | ― | ― | ― | 14.03% | |
51 Neutral | ¥24.81B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥50.09B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.66B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.93B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4575
CanBas Co., Ltd.
715.00
-306.00
-29.97%
JP:4593
Healios KK
366.00
63.00
20.79%
JP:4599
StemRIM Inc.
313.00
-7.00
-2.19%
JP:4978
ReproCELL Inc.
177.00
32.00
22.07%
JP:7774
Japan Tissue Engineering Co., Ltd.
595.00
-36.00
-5.71%
JP:7776
CellSeed Inc.
297.00
-315.00
-51.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.